Bicycle Therapeutics appoints Rolf H. Günther, M.D., Ph.D. as CEO

04-Apr-2012 - United Kingdom

Bicycle Therapeutics announced the appointment of Rolf Günther, MD, PhD as Chief Executive Officer.  Bicycle has developed a proprietary bicyclic peptide technology that enables the discovery of a new class of drug candidates with antibody-like selectivity and specificity that can be manufactured with economics similar to new chemical entities.  Under Dr. Günther’s leadership, the company will apply the technology to drug discovery projects addressing a wide range of challenging targets, through its own programmes and by entering into corporate partnerships.

Dr. Günther has over 21 years of pharmaceutical industry experience with an extensive background in drug development, biologics and speciality pharmaceuticals.   He previously served as CEO and COO of Affimed, a monoclonal antibody company, since 2004 and has successfully developed its clinical product portfolio in oncology.  Dr. Günther will continue to be engaged as COO in Affimed in a part time position until August this year.  He held the position of VP and General Manager of the Critical Care business unit of Aventis Behring, which he joined as VP Global Clinical Research in 1996, and was responsible for successful drug approvals in the US and Europe.

Other news from the department people

More news from our other portals

So close that even
molecules turn red...